Sort   by:  
 Page size 
UnknownClinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Not available
S-EPMC4647692 | biostudies-literature
UnknownMetastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).
Not available
S-EPMC8327489 | biostudies-literature
UnknownNeoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Not available
S-EPMC4304382 | biostudies-literature
UnknownDecision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Not available
S-EPMC7375561 | biostudies-literature
UnknownPredictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Not available
S-EPMC7078275 | biostudies-literature
Sort   by:  
 Page size